Antiphospholipid syndrome in 2014: More clinical manifestations, novel pathogenic players and emerging biomarkers

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Meroni, Pier L ^a,b   Chighizola, Cecilia B ^a,b   Rovelli, Francesca ^a   Gerosa, Maria ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; LIPOCORTIN 2; LIPOCORTIN 5; PHOSPHATIDYLETHANOLAMINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG; VIMENTIN ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL CLASSIFICATION; CLINICAL FEATURE; HUMAN; LABORATORY DEVICE; LABORATORY DIAGNOSIS; REVIEW; SYSTEMATIC REVIEW (TOPIC);

ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; HUMANS;

EID: 84899102723     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4549     Document Type: Review

References (90)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306. 10.1111/j.1538-7836.2006.01753.x, 16420554.
2. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, Zeher MM, Tincani A, Kontopoulou-Griva I, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Roch B, Fernández-Nebro A, Piette JC, Espinosa G, Bucciarelli S, Pisoni CN, Bertolaccini ML, et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009, 68:1428-1432.
3. Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the 'CAPS Registry'. Semin Thromb Hemost 2012, 38:333-338.
4. Shoenfeld Y, Meroni PL, Toubi E. Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?. Curr Opin Rheumatol 2009, 21:495-500. 10.1097/BOR.0b013e32832effdd, 19593144.
5. Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus 2010, 19:424-427. 10.1177/0961203309360545, 20353981.
6. Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 2005, 14:499-504. 10.1191/0961203305lu2145rr, 16130503.
7. Frances C. Dermatological manifestations of Hughes' antiphospholipid antibody syndrome. Lupus 2010, 19:1071-1077. 10.1177/0961203310370343, 20693200.
8. Zuily S, Huttin O, Mohamed S, Marie PY, Selton-Suty C, Wahl D. Valvular heart disease in antiphospholipid syndrome. Curr Rheumatol Rep 2013, 15:320.
9. Tektonidou MG. Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. Clin Rev Allergy Immunol 2009, 36:131-140. 10.1007/s12016-008-8112-z, 19048414.
10. Brey RL, Muscal E, Chapman J. Antiphospholipid antibodies and the brain: a consensus report. Lupus 2011, 20:153-157. 10.1177/0961203310396748, 21303831.
11. Hanly JG, Urowitz MB, Su L, Gordon C, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Wallace DJ, Clarke AE, Ginzler E, Merrill JT, Isenberg DA, Rahman A, Petri M, Fortin PR, Gladman D, Bruce IN, Steinsson K, Dooley M, Khamashta MA, Alarcón GS, Fessler BJ, Ramsey-Goldman R, Manzi S, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis 2012, 71:1502-1509.
12. Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphopholipid syndrome. Arch Intern Med 2006, 166:2278-2284. 10.1001/archinte.166.20.2278, 17101948.
13. Gerosa M, Poletti B, Pregnolato F, Lafronza A, Silani V, Meroni PL, Riboldi P. Antiphospholipid syndrome and systemic lupus erythematosus: what's new about cognitive impairment. J Neurol 2009, 256:S190.
14. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, De Micheli V, Gresele P, Tonello M, Ghirarduzzi A, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011, 118:4714-4718. 10.1182/blood-2011-03-340232, 21765019.
15. Ruffatti A, Tonello M, Visentin MS, Bontadi A, Hoxha A, De Carolis S, Botta A, Salvi S, Nuzzo M, Rovere-Querini P, Canti V, Mosca M, Mitic G, Bertero MT, Pengo V, Boffa MC, Tincani A. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre case-control study. Rheumatology 2011, 50:1684-1689. 10.1093/rheumatology/ker139, 21652586.
16. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheum 2011, 7:330-339.
17. Pengo V, Banzato A, Denas G, Jose SP, Bison E, Hoxha A, Ruffatti A. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013, 12:832-834. 10.1016/j.autrev.2012.11.008, 23219767.
18. De Laat HB, Derksen RHWM, Urbanus RT, Roest M, de Groot PG. B2-glycoprotein I dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004, 104:3598-3602. 10.1182/blood-2004-03-1107, 15315975.
19. Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, Montecucco C, Rossi S, Caramaschi P, Biasi D, Doria A, Rampudda M, Monica N, Fischetti F, Picillo U, Brucato A, Salvan E, Vittorio P, Meroni P, Tincani A, Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011, 70:1083-1086. 10.1136/ard.2010.142042, 21285115, Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology.
20. Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K, Horita T, Yasuda S, Koike T. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012, 64:504-512. 10.1002/art.33340, 21953404.
21. Devreese KM. Antiphospholipid antibodies: evaluation of the thrombotic risk. Thrombosis Res 2012, 130:S37-S40.
22. Meijide H, Sciascia S, Sanna G, Khamashta MA, Bertolaccini ML. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies. A systematic review. Autoimmun Rev 2013, 12:421-425. 10.1016/j.autrev.2012.08.002, 22951216.
23. Murthy V, Willis R, Romay-Penabad Z, Ruiz-Limon P, Martinez-Martinez LA, Jatwani S, Jajoria P, Seif A, Alarcon GS, Papalardo E, Liu J, Vilà LM, McGwin G, McNearney TA, Maganti R, Sunkureddi P, Parekh T, Tarantino M, Akhter E, Fang H, Gonzalez EB, Binder WB, Norman GL, Shums Z, Teodorescu M, Reveille JD, Petri M, Pierangeli SP. Value of isolated IgA anti-β2-glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 2013, 65:3186-3193. 10.1002/art.38131, 23983008.
24. Gardiner C, Hills J, Machin SJ, Cohen H. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 2013, 22:18-25. 10.1177/0961203312460722, 22988029.
25. Pregnolato F, Chighizola C. Phospholipid autoantibodies (non-anticardiolipin)-anti-prothrombin antibodies. The Autoantibodies 2014, 741-749. New York: Elsevier, Shoenfeld Y, Gershwin E, Meroni PL, 3.
26. Pregnolato F, Chighizola CB, Encabo S, Shums Z, Norman GL, Tripodi A, Chantarangkul V, Bertero T, De Micheli V, Borghi MO, Meroni PL. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. Immunologic Res 2013, 56:432-438.
27. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta M, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome: a systematic review. Thromb Haemost 2014, 111:354-364.
28. Fleck RA, Rapaport SI, Rao LVM. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988, 72:512-519.
29. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996, 75:721-724.
30. Horback DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996, 76:916-924.
31. Puurunen M, Vaarala O, Julkunen H, Aho K, Palosuo T. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996, 80:16-22. 10.1006/clin.1996.0089, 8674235.
32. Swadzba J, De Clerck LS, Stevens WJ, Bridts CH, van Cotthem KA, Musial J, Jankowski M, Szczeklik A. Anti-cardiolipin, antibeta2glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol 1997, 24:1710-1715.
33. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997, 77:486-491.
34. Bertolaccini ML, Atsumi T, Khamashta MA, Amengual O, Hughes GR. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 1998, 25:1104-1108.
35. Forastiero R, Martinuzzo ME, Adamczuk Y, Carreras LO. Occurrence of anti-prothrombin antibodies and anti-beta2glycoprotein I antibodies in patients with a history of thrombosis. J Lab Clin Med 1999, 134:610-615. 10.1016/S0022-2143(99)90101-4, 10595789.
36. Munoz-Rodriguez FJ, Reverter JC, Font J, Tàssies D, Cervera R, Espinosa G, Carmona F, Balasch J, Ordinas A, Ingelmo M. Prevalence and clinical significance of anti-prothrombin antibodies in patients with systemic lupus erythematosus or with primary anti-phospholipid syndrome. Haematologica 2000, 85:632-637.
37. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, Koike T. Association of autoantibodies against the phosphatidylserine-prothrobin complex with manifestations of the antiphospholipid syndrome and in the presence of lupus anticoagulant. Arthritis Rheum 2000, 43:1982-1993. 10.1002/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2, 11014348.
38. Galli M, Dlott J, Norbis F, Ruggeri L, Cler L, Triplett DA, Barbui T. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests. Thromb Haemost 2000, 84:1012-1016.
39. Nojima H, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Kitani T, Iwatani Y, Kanakura Y. Anti-prothrombin antibodies combined with lupus anticoagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001, 114:647-654. 10.1046/j.1365-2141.2001.02950.x, 11552993.
40. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Iwatani Y, Kanakura Y. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001, 47:1008-1015.
41. Simmelink MJA, De Groot PG, Derksen RHWM. A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis. J Thromb Haemost 2002, 1:735-739.
42. Salcido-Ochoa F, Cabiedes J, Alarcón-Segovia D, Cabral AR. Antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. J Clin Rheumatol 2002, 8:251-255. 10.1097/00124743-200210000-00004, 17041380.
43. Von Landenberg P, Matthias T, Zaech J, Schultz M, Lorber M, Blank M, Shoenfeld Y. Anti-prothrombin antibodies are associated with pregnancy loss in patients with the antiphospholipid syndrome. Am J Reprod Med 2003, 49:51-56.
44. Musial J, Swadzba J, Motyl A, Iwaniec T. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis. J Rheumatol 2003, 30:723-730.
45. Ishikura K, Wada H, Kamikura Y, Hattori K, Fukuzawa T, Yamada N, Nakamura M, Nobori T, Nakano T. High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis. Am J Hematol 2004, 76:338-742. 10.1002/ajh.20124, 15282665.
46. Koskenmies S, Vaarala O, Widen E, Kere J, Palosuo T, Julkunen H. The association of antibodies to cardiolipin, beta 2-glycoprotein I, prothrombin, and oxidized low-density lipoprotein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus. Scand J Rheumatol 2004, 33:246-252. 10.1080/03009740410005386, 15370721.
47. Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 2005, 93:289-297.
48. Bizzaro N, Tonutti E, Villalta D, Tampoia M, Tozzoli R. Prevalence and clinical correlation of anti-phospholipid binding protein antibodies in anti-cardiolipin negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch Pathol Lab Med 2005, 129:61-68.
49. Forastiero R, Martinuzzo M, Pombo G, Puente D, Rossi A, Celebrin L, Bonaccorso S, Aversa L. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005, 3:1231-1238. 10.1111/j.1538-7836.2005.01295.x, 15946213.
50. Gould T, Tikly M, Asherson R, Loizou S, Singh S. Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with systemic lupus erythematosus. Scand J Rheumatol 2006, 35:29-34. 10.1080/03009740510026913, 16467038.
51. Tsutumi A, Hayashi T, Chino Y, Mamura M, Goto D, Matsumoto I, Ito S, Sumida T. Significance of anti-prothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the anti-phosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays. Mod Rheumatol 2006, 16:158-164. 10.3109/s10165-006-0481-7, 2778700, 16767554.
52. Nojima J, Iwatani Y, Suehisa E, Suehisa E, Kuratsune H, Kanakura Y. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica 2006, 91:699-702.
53. Bizzaro N, Ghirardello A, Zampieri S, Iaccarino L, Tozzoli R, Ruffatti A, Villalta D, Tonutti E, Doria A. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15 year longitudinal study. J Thromb Haemost 2007, 5:1158-1164. 10.1111/j.1538-7836.2007.02532.x, 17388963.
54. Sailer T, Vormittag R, Zoghlami C, Koder S, Quehenberger P, Male C, Pabinger I. The clinical significance of anti-prothrombin antibodies for risk assessment of thromboembolism in patients with lupus anticoagulant. Thromb Res 2007, 120:295-302. 10.1016/j.thromres.2007.01.001, 17328943.
55. Bardin N, Alessi MC, Dignat-George F, Vague IJ, Sampol J, Harlé JR, Sanmarco M. Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?. Immunobiology 2007, 212:557-565. 10.1016/j.imbio.2007.02.001, 17678713.
56. Jakowski TD, Wilson AR, Hill HR, Branch WD, Tebo AE. Autoantibodies against phosphatidylserine, prothrombin and phosphatidylserine-prothrombin complex: identical or distinct diagnostic tools for antiphospholipid syndrome?. Clin Chim Acta 2009, 410:19-24. 10.1016/j.cca.2009.09.006, 19751711.
57. Szodoray P, Tarr T, Tumpek J, Kappelmayer J, Lakos G, Poor G, Szegedi G, Kiss E. Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus. Autoimmunity 2009, 42:497-506. 10.1080/08916930902882731, 19626489.
58. Pengo V, Denas G, Bison E, Banzato A, Jose SP, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, De Candia E, Montaruli B, Marietta M, Testa S, Barcellona D, Tripodi A. Prevalence and significance of anti-prothrombin antibodies in patients with lupus anticoagulant (LA). Thromb Res 2010, 126:150-153. 10.1016/j.thromres.2010.05.018, 20542544.
59. Marozio L, Curti A, Botta G, Canuto EM, Salton L, Tavella AM, Benedetto C. Anti-prothrombin antibodies are associated with adverse pregnancy outcome. Am J Reprod Immunol 2011, 66:404-409. 10.1111/j.1600-0897.2011.01031.x, 21682791.
60. Hoxha A, Ruffatti A, Pittoni M. The clinical significance of autoantibodies directed against prothrombin in primary antiphospholipid syndrome. Clin Chim Acta 2012, 413:911-913. 10.1016/j.cca.2012.02.004, 22349599.
61. Sater MS, Finan RR, Abu-Hijleh FM, Abu-Hijleh TM, Almawi WY. Anti-phosphatidylserine, anti-cardiolipin, anti-beta2glycoprotein I and anti-prothrombin antibodies in recurrent miscarriage at 8-12 gestational weeks. Eur J Obstet Gynecol Reprod Biol 2012, 163:170-174. 10.1016/j.ejogrb.2012.04.001, 22555404.
62. Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/antibeta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies. Co-existence of these antibodies enhance ADP-induced platelet activation. Thromb Haemost 2004, 91:967-976.
63. Atsumi T, Koike T. Anti-prothrombin antibody: why do we need more assays?. Lupus 2010, 19:436-439. 10.1177/0961203310361487, 20353984.
64. Žigon P, Ambrožič A, Čučnik S, Kveder T, Rozman B, Božič B. Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies. Clin Chem Lab Med 2011, 49:1011-1018.
65. Vlagea A, Gil A, Cuesta MV, Arribas F, Diez J, Lavilla P, Pascual-Salcedo D. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. Clin Appl Thromb Hemost 2013, 19:289-296.
66. Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 2012, 10:2512-2518. 10.1111/jth.12014, 23025466.
67. Shoenfeld Y, Krause I, Kvapil F, Sulkes J, Lev S, von Landenberg P, Font J, Zaech J, Cervera R, Piette JC, Boffa MC, Khamashta MA, Bertolaccini ML, Hughes GR, Youinou P, Meroni PL, Pengo V, Alves JD, Tincani A, Szegedi G, Lakos G, Sturfelt G, Jönsen A, Koike T, Sanmarco M, Ruffatti A, Ulcova-Gallova Z, Praprotnik S, Rozman B, Lorber M, Vriezman VB, Blank M. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol 2003, 23:377-383. 10.1023/A:1025321617304, 14601646.
68. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012, 12:313-317. 10.1016/j.autrev.2012.05.006, 22652408.
69. de Laat B, de Groot PG. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep 2011, 13:70-76. 10.1007/s11926-010-0144-8, 3016149, 21046294.
70. de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, Ruffatti A, Rozman B, Kveder T, de Moerloose P, Boehlen F, Rand J, Ulcova-Gallova Z, Mertens K, de Groot PG. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009, 7:1767-1773. 10.1111/j.1538-7836.2009.03588.x, 19694946.
71. Zuily S, De Laat B, Regnault V, Guillemin F, Kaminsky P, Albesa R, Norman G, De Groot PG, Lecompte T, Wahl D. Autoantibodies against domain I of beta2-glycoprotein indicate an increased risk for thrombosis in antiphospholipid patients, A prospective cohort study. J Thromb Haemost 2013, 11:S3.
72. Agmon-Levin N, Seguro L, Rosario C, Mahler M, Gatto M, Tomer N, Leon E, Doria A, Kovács L, Costedoat-Chalumeau N, Gilburd B, Shoenfeld Y. Anti-β2GPI-DI antibodies are a marker of APS severity. Arthritis Rheum 2013, 65:S1.
73. Andreoli L, Nalli C, Borghi MO, Pregnolato F, Grossi C, Zangola A, Allegri F, Gerosa M, Mahler M, Norman GL, Meroni PL, Tincani A. Domain I is the main specificity of anti-beta2 GPI in systemic autoimmune diseases. Arthritis Rheum 2013, 65:S4.
74. Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep 2014, 16:402.
75. Willis R, Mahler M, Pregnolato F, Pericleous C, Rahman A, Ioannou J, Giles I, Lakos G, Albesa R, Zohoury N, Meroni PL, Pierangeli S. Clinical evaluation of two anti-Beta2glycoprotein I Domain 1 autoantibody assays to aid in the diagnosis and risk assessment of the antiphospholipid syndrome. Arthritis Rheum 2013, 65:S3.
76. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007, 56:280-290. 10.1002/art.22306, 2117024, 17195232.
77. Agostinis C, Durigutto P, Sblattero D, Borghi M, Grossi C, Bulla R, Macor P, Meroni PL, Tedesco F. A human monoclonal antibody against domain I of β2-glycoprotein I prevents clotting and fetal loss induced by polyclonal anti-phospholipid antibodies in animal models. Arthritis Rheum 2013, 65:S245.
78. Staub HL, Bertolaccini ML, Khamashta MA. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev 2012, 12:230-234. 10.1016/j.autrev.2012.07.008, 22796282.
79. Sugi T, Matsubayashi H, Inomo A, Dan L, Makino T. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res 2004, 30:326-332. 10.1111/j.1447-0756.2004.00206.x, 15238112.
80. Conti F, Alessandri C, Sorice M, Capozzi A, Longo A, Garofalo T, Misasi R, Bompane D, Hughes GR, Khamashta MA, Valesini G. Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome. Clin Exp Immunol 2012, 167:429-437. 10.1111/j.1365-2249.2011.04532.x, 3374275, 22288586.
81. Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de Laat B, Forastiero R, Kutteh WH, Lambert M, Matsubayashi H, Murthy V, Petri M, Rand JH, Sanmarco M, Tebo AE, Pierangeli SS. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus 2011, 20:191-205. 10.1177/0961203310397082, 21303836.
82. Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta MA. Seronegative antiphospholipid syndrome. Rheumatology 2013, 52:1358-1367. 10.1093/rheumatology/ket126, 23502076.
83. Yodfat O, Blank M, Krause I, Shoenfeld Y. The pathogenic role of anti-phosphatidylserine antibodies: active immunization with the antibodies leads to the induction of antiphospholipid syndrome. Clin Immunol Immunopathol 1996, 78:14-20. 10.1006/clin.1996.0003, 8599879.
84. Grossi C, Borghi MO, Papaardo E, Pierangeli SS, Meroni PL. A more specific immunoassay for the diagnosis of APS. Arthritis Rheum 2013, 65:S5.
85. Sciascia S, Sanna G, Murru V, Khamashta MA, Bertolaccini ML. The clinical value of testing for Aphl, a new ELISA kit with a unique phospholipid mixture in patients with systemic lupus erythematosus (SLE). Arthritis Rheum 2013, 65:S1.
86. Cesarman-Maus G, Ríos-Luna NP, Deora AB, Huang B, Villa R, Cravioto Mdel C, Alarcón-Segovia D, Sánchez-Guerrero J, Hajjar KA. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006, 107:4375-4382. 10.1182/blood-2005-07-2636, 1895790, 16493010.
87. Lambrianides A, Carroll CJ, Pierangeli SS, Pericleous C, Branch W, Rice J, Latchman DS, Townsend P, Isenberg DA, Rhaman A, Giles IP. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 2010, 184:6622-6628. 10.4049/jimmunol.0902765, 2898497, 20483743.
88. Meroni PL, Raschi E, Grossi C, Pregnolato F, Trespidi L, Acaia B, Borghi MO. Obstetric and vascular APS: same autoantibodies but different diseases?. Lupus 2012, 21:708-710. 10.1177/0961203312438116, 22635208.
89. Agostinis C, Biffi S, Garrovo C, Durigutto P, Lorenzon A, Bek A, Bulla R, Grossi C, Borghi MO, Meroni P, Tedesco F. In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions. Blood 2011, 118:4231-4238. 10.1182/blood-2011-01-333617, 21791419.
90. Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. J Thromb Haemost 2011, 9:275-282.